WO2007014992A3 - Anticorps diriges contre le recepteur du ldl - Google Patents

Anticorps diriges contre le recepteur du ldl Download PDF

Info

Publication number
WO2007014992A3
WO2007014992A3 PCT/FR2006/001807 FR2006001807W WO2007014992A3 WO 2007014992 A3 WO2007014992 A3 WO 2007014992A3 FR 2006001807 W FR2006001807 W FR 2006001807W WO 2007014992 A3 WO2007014992 A3 WO 2007014992A3
Authority
WO
WIPO (PCT)
Prior art keywords
directed against
ldl receptor
antibodies directed
cirrhosis
ldl
Prior art date
Application number
PCT/FR2006/001807
Other languages
English (en)
Other versions
WO2007014992A2 (fr
Inventor
Christian Behrens
Christine Gaucher
Jean-Francois Prost
Jamila Najib
Original Assignee
Lab Francais Du Fractionnement
Christian Behrens
Christine Gaucher
Jean-Francois Prost
Jamila Najib
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement, Christian Behrens, Christine Gaucher, Jean-Francois Prost, Jamila Najib filed Critical Lab Francais Du Fractionnement
Priority to JP2008524539A priority Critical patent/JP2009502189A/ja
Priority to AU2006274752A priority patent/AU2006274752A1/en
Priority to EP06794207A priority patent/EP1937722A2/fr
Priority to CA002618050A priority patent/CA2618050A1/fr
Publication of WO2007014992A2 publication Critical patent/WO2007014992A2/fr
Publication of WO2007014992A3 publication Critical patent/WO2007014992A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un anticorps monoclonal dirigé contre le récepteur humain des LDL (Low Density Lipoprotein), se liant au peptide correspondant aux acides aminés 280-307 (SEQ ID NO : 1) de la séquence peptidique du récepteur des LDL, son utilisation comme médicament, une composition pharmaceutique contenant cet anticorps, ainsi que son utilisation dans les analyses immunohistochimiques de tissus cancéreux, sains ou cirrhoses, en western blot, en ELISA ou en test de quantification in vivo.
PCT/FR2006/001807 2005-08-03 2006-07-25 Anticorps diriges contre le recepteur du ldl WO2007014992A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2008524539A JP2009502189A (ja) 2005-08-03 2006-07-25 Ｌｄｌ受容体に対する抗体
AU2006274752A AU2006274752A1 (en) 2005-08-03 2006-07-25 Antibodies directed against an LDL receptor
EP06794207A EP1937722A2 (fr) 2005-08-03 2006-07-25 Anticorps dirigés contre le récepteur du ldl
CA002618050A CA2618050A1 (fr) 2005-08-03 2006-07-25 Anticorps diriges contre le recepteur du ldl

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0508281 2005-08-03
FR0508281A FR2889532B1 (fr) 2005-08-03 2005-08-03 Anticorps diriges contre le recepteur du ldl

Publications (2)

Publication Number Publication Date
WO2007014992A2 WO2007014992A2 (fr) 2007-02-08
WO2007014992A3 true WO2007014992A3 (fr) 2007-04-19

Family

ID=35883519

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/001807 WO2007014992A2 (fr) 2005-08-03 2006-07-25 Anticorps diriges contre le recepteur du ldl

Country Status (6)

Country Link
EP (1) EP1937722A2 (fr)
JP (1) JP2009502189A (fr)
AU (1) AU2006274752A1 (fr)
CA (1) CA2618050A1 (fr)
FR (1) FR2889532B1 (fr)
WO (1) WO2007014992A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
FR2959229B1 (fr) 2010-04-21 2013-01-18 Vect Horus Derives peptidiques, leur preparation et leurs utilisations
EP3038657A2 (fr) 2013-08-28 2016-07-06 Bioasis Technologies Inc. Conjugués comportant des régions fc modifiées pour cibler le snc et méthodes pour les utiliser
CA3128035A1 (fr) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Polytherapies pour l'administration dans l'ensemble de la barriere hemato-encephalique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000279174A (ja) * 1999-03-30 2000-10-10 Bml Inc ヒトｌｄｌレセプターに対するモノクローナル抗体及びこれを用いる家族性高脂血症の判定方法
WO2001068710A1 (fr) * 2000-03-13 2001-09-20 Applied Research Systems Ars Holding N.V. Anticorps monoclonaux anti-recepteur de ldl humain, leur preparation et utilisation
JP2004529080A (ja) * 2000-10-25 2004-09-24 アグネッロ，ヴィンセント Ｈｃｖ、他のフラビウイルス科ウイルス、および血液中で低密度リポタンパク質または超低密度リポタンパク質と複合体を形成するその他のあらゆるウイルスによる感染を細胞中へのウイルス侵入を抑制することによって防止する方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000279174A (ja) * 1999-03-30 2000-10-10 Bml Inc ヒトｌｄｌレセプターに対するモノクローナル抗体及びこれを用いる家族性高脂血症の判定方法
WO2001068710A1 (fr) * 2000-03-13 2001-09-20 Applied Research Systems Ars Holding N.V. Anticorps monoclonaux anti-recepteur de ldl humain, leur preparation et utilisation
JP2004529080A (ja) * 2000-10-25 2004-09-24 アグネッロ，ヴィンセント Ｈｃｖ、他のフラビウイルス科ウイルス、および血液中で低密度リポタンパク質または超低密度リポタンパク質と複合体を形成するその他のあらゆるウイルスによる感染を細胞中へのウイルス侵入を抑制することによって防止する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 13 5 February 2001 (2001-02-05) *

Also Published As

Publication number Publication date
FR2889532B1 (fr) 2007-10-12
EP1937722A2 (fr) 2008-07-02
CA2618050A1 (fr) 2007-02-08
WO2007014992A2 (fr) 2007-02-08
AU2006274752A1 (en) 2007-02-08
JP2009502189A (ja) 2009-01-29
FR2889532A1 (fr) 2007-02-09

Similar Documents

Publication Publication Date Title
WO2005120557A3 (fr) Inhibition du recepteur proteique stimulant les macrophages (ron)
JP2004532817A5 (fr)
EP2399936A3 (fr) Anticorps anti-CD154
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
WO2005117952A3 (fr) Methodes de traitement dans lesquelles des proteines de liaison de l'albumine sont utilisees
EP2332988A3 (fr) Anticorps monoclonaux et leurs procédés d'utilisation pour la détection de maladie cervicale
WO2007059136A3 (fr) Anticorps pth anti-rankl/molecules chimeres pthrp
EP2368913A3 (fr) Anticorps glyco-modifiés
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
EP2716658A3 (fr) Anticorps et procédés de fabrication et d'utilisation de ceux-ci
WO2005018424A3 (fr) Anticorps specifiques de la proteine amyloide fibrillaire et procedure permettant de detecter des depots de proteines amyloides fibrillaires
EP3447074A3 (fr) Protéines de liaison à un antigène humain qui se lient à un complexe comprenant bêta-klotho et un récepteur de fgf
WO2009085216A3 (fr) Compositions et méthodes de détection ou d'élimination de cellules sénescentes pour le diagnostic ou le traitement de maladies
MX2008009886A (es) Anticuerpos que enlazan par-2.
IL191788A0 (en) Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies
WO2000005249A3 (fr) Peptides synthetiques et procedes d'utilisation de ceux-ci dans des therapies de maladies auto-immunes
WO2004081028A3 (fr) Fragments de peptides d'allergene et leur utilisation
WO2005087811A3 (fr) Recepteurs des oestrogenes et procedes d'utilisation associes
EP3300739A3 (fr) Anticorps et molécules correspondantes se liant aux protéines 161p2f10b
WO2002036625A3 (fr) Polypeptides de prokineticine, et methodes et compositions associees
WO2001068708A3 (fr) ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a)
WO2007039256A3 (fr) Domaines de liaison de proteines de la famille proteinique des molecules de guidage repulsif (rgm), fragments fonctionnels de ces domaines et leur utilisation
ATE460430T1 (de) Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper
EP1908837A3 (fr) Protéines humaines réceptrices, réactifs associés et procédés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008524539

Country of ref document: JP

Ref document number: 2618050

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006274752

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006794207

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006274752

Country of ref document: AU

Date of ref document: 20060725

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006274752

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006794207

Country of ref document: EP